McKesson Corporation
MCK · Healthcare
$906.77
Indlæser diagram…
Nyheder
Seneste overskrifter for denne aktie
AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie has successfully diversified beyond its blockbuster Humira with strong immunology drugs (Skyrizi and Rinvoq), while Pfizer is leveraging its cash position to build oncology and GLP-1 pipelines. Despite AbbVie's stronger growth trajectory, Pfizer offers better valuation metrics with lower P/E and P/S ratios, making it the preferred choice for long-term value investors willing to wait for new product launches.
Cencora Raises 2026 EPS Outlook as Specialty Businesses Strengthen
Cencora (COR) raised its fiscal 2026 adjusted EPS guidance to $17.75-$17.95 following stronger-than-expected third-quarter results. The company's U.S. segment profit grew 15.9% driven by specialty sales and GLP-1 demand, while international operating income rose 20.8%. However, headwinds from lower-margin GLP-1 products, manufacturer price reductions, and higher financing costs tempered upside. The stock maintains a Zacks Rank #3 (Hold) rating.
Is Generics Still a Quiet Profit Engine for Cardinal Health?
Cardinal Health's generics business continues to be a steady profit contributor, with fiscal 2026 volume growth exceeding long-term planning assumptions of 2-3%. The company expects fiscal 2027 to benefit from new generic launches, brand-to-generic conversions, and stable Red Oak program dynamics, supporting projected Pharma segment profit growth of 8-11%. Peers McKesson and Cencora also show strength in their pharmaceutical distribution and generics portfolios.
Here's How Much a $1000 Investment in McKesson Made 10 Years Ago Would Be Worth Today
A $1,000 investment in McKesson (MCK) made in September 2016 would be worth $4,795.36 as of September 1, 2026, representing a 379.54% gain and significantly outperforming the S&P 500's 254.05% return. The pharmaceutical distributor is benefiting from growth in specialty pharmaceuticals, oncology services, and GLP-1 medications, with FY26 revenues reaching $403.4 billion and adjusted EPS up 18% year-over-year. Analysts remain optimistic with recent earnings estimate revisions and raised fiscal 2027 guidance.
McKesson Corporation: Ademi LLP Investigates Claims for Damages
McKesson disclosed a data breach on August 25, 2026, affecting 284 million records belonging to tens of millions of patients. Compromised information includes personal identities, healthcare identifiers, medical records, prescription data, and highly sensitive health information. Ademi LLP is investigating potential data privacy claims and advising affected individuals to monitor financial accounts and consider credit protection measures.